NIIMBL funding awarded to bring gene therapies to market faster
Cytiva and BioCentriq, a new Jersey-based cell and gene therapy contract development and manufacturing organisation (CDMO), have been awarded funding from the National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL), a public-private partnership whose mission is to accelerate biopharmaceutical innovation. Viral clearance is a key regulatory requirement… Read More